刘艳红;叶庆;
LIU Yan-hong;YE Qing;Department of Pathology,Nanjing Drum Tower Hospital,The Affiliated Hospital of Nanjing University Medical School;Biobank,Nanjing Drum Tower Hospital,The Affiliated Hospital of Nanjing University Medical School;Department of Pathology,The First Affiliated Hospital of University of Science and Technology of China;Intelligent Pathology Institute,The First Affiliated Hospital of University of Science and Technology of China;

• 1:南京大学医学院附属鼓楼医院病理科
• 2:南京大学医学院附属鼓楼医院生物样本库
• 3:中国科学技术大学附属第一医院临床病理中心
• 4:中国科学技术大学附属第一医院智慧病理学研究所

摘要(Abstract)：

近年来,在"健康中国"大背景下,精准医疗和生物样本库迎来了快速发展的黄金时期。精准医疗时代,生物样本库作为医疗行业的新兴领域,有其自身发展趋势和特点,表现为发展进程需标准化和规范化、高度依赖信息化建设、离不开多中心联盟和资源共享、需多学科融合支撑等。随着精准医学的不断发展,生物样本库已从生物样本和信息资源的整合平台,逐步发展为精准医疗研究的支撑服务平台及成果转化的合作平台。此外,生物样本库发展进程中尚存在数据安全、隐私保护及可持续发展运营等问题,亟待规范和完善。
In recent years, in the context of "Healthy China", precision medicine and biobanks have ushered in a golden period of rapid development. In the era of precision medicine, as an emerging field in the medical industry, biobanks have their own development trend and characteristics: the development process needs standardization, highly relies on information technology, is inseparable from multi-center alliance and resource sharing, and needs the support of multidisciplinary integration. With the continuous development of precision medicine, biobanks developed from its infancy stage, a platform of biological samples and information resource integration, into a service platform of precision medical study support and a platform of transformation cooperation. In addition, during the development stage of biobanks, there are problems of data security, privacy protection and sustainable operation.

关键词(KeyWords)： 精准医疗;生物样本库;发展特点;建设
precision medicine;biobank;developmental feature;construction

Abstract:

Keywords:

基金项目(Foundation): 江苏省重大疾病生物资源样本库妇产疾病子库(BM2015004);江苏省重大疾病生物资源样本库开放课题(SBK202006001,SBK202006002,SBK202006003)~~

作者(Authors): 刘艳红;叶庆;
LIU Yan-hong;YE Qing;Department of Pathology,Nanjing Drum Tower Hospital,The Affiliated Hospital of Nanjing University Medical School;Biobank,Nanjing Drum Tower Hospital,The Affiliated Hospital of Nanjing University Medical School;Department of Pathology,The First Affiliated Hospital of University of Science and Technology of China;Intelligent Pathology Institute,The First Affiliated Hospital of University of Science and Technology of China;

参考文献(References)：

• [1] National Research Council of the National Academies.Toward Precision Medicine:Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease[M].Washington (DC):the National Academies Press,2011.
• [2] McGrath S,Ghersi D.Building towards precision medicine:empowering medical professionals for the next revolution[J].BMC Med Genomics,2016,9:23.
• [3] 徐鹏辉.美国启动精准医疗计划[J].世界复合医学，2015,1:44- 46.[3] Xu PH.United States Launched Precision Medicine Initiative[J].Shi Jie Fu He Yi Xue,2015,1:44- 46.
• [4] 吕霁航，赵丹惠，韩亮.精准医疗的研究进展[J].中国实验诊断学，2017,21:152- 154.
• [5] Thomas A,Pommier Y.Targeting Topoisomerase I in the Era of Precision Medicine[J].Clin Cancer Res,2019,25:6581- 6589.
• [6] Jin N,Bi AW,Lan XJ,et al.Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer[J].Nat Commun,2019,10:2701.
• [7] Büttner R,Gosney JR,Skov BG,et al.Programmed Death-Ligand 1 Immunohistochemistry Testing:A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer[J].J Clin Oncol,2017,35:3867- 3876.
• [8] Herbst RS,Baas P,Kim DW,et al.Pembrolizumab versus docetaxel for previously treated,PD-L1-positive,advanced non-small-cell lung cancer (KEYNOTE-010):a randomised controlled trial[J].Lancet,2016,387:1540- 1550.
• [9] Wolchok JD,Chiarion-Sileni V,Gonzalez R,et al.Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma[J].N Engl J Med,2017,377:1345- 1356.
• [10] HOMME DP.Dynamics of China's provincial-level specialization in strategic emerging industries[J].Res Policy,2016,45:1586- 1603.
• [11] 郜恒骏，杜莉利，张小燕，等.生物样本库发展的现状、机遇与挑战[J].协和医学杂志，2018,9:172- 176.[11] Gao HJ,Du LL,Zhang XY,et al.Status,Opportunities and Challenges of Biobanks[J].Xie He Yi Xue Za Zhi,2018,9:172- 176.
• [12] 国务院.“十三五”国家战略性新兴产业发展规划[EB/OL].(2016- 11- 29).http://www.gov.cn/zhengce/content/2016- 12/19/content_5150090.htm.
• [13] 白莉华，申锷，杨军，等.生物样本库大数据的伦理与法律问题研究[J].中国医学伦理学，2017,30:1206- 1212.[13] Bai LH,Shen E,Yang J,et al.Analysis on the Ethical and Legal Issues of Big Data of Biobank[J].Zhongguo Yi Xue Lun Li Xue,2017,30:1206- 1212.
• [14] 杨咪，杨小丽.理性审视精准医疗发展中的问题及其对策探讨[J].中国全科医学，2017,20:886- 890.[14] Yang M,Yang XL.Problems in the Development of Precision Medicine and Corresponding Countermeasures[J].Zhongguo Quan Ke Yi Xue,2017,20:886- 890.